ClinicalTrials.gg
CompletedNCT05163808Updated Aug 31, 2026

A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

A Phase 2/3 interventional study of zatolmilast and Placebo in Fragile X Syndrome, sponsored by Tetra Discovery Partners. Completed at 17 sites in United States. Open to male participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Tetra Discovery Partners (part of Shionogi) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
9 Years to 18 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Fragile X Syndrome with a site in United States — 11 open to participants now, 16 under way, 2 of them phase 3. Fragile X Syndrome · United States.

Enrollment
12th of 68
163 · median 60
Started
2022
with 6 others
Phase 2/3
5 of 82
none open now
Registered
65th of 82
by date
Lead sponsor
4 of 82
Tetra Discovery Partners

Among the 82 studies in Fragile X Syndrome with a site in United States, this one is the 12th largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2022, is one of 5 in phase 2/3, and was the 65th registered.

Fragile X Syndrome

115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.

Browse Fragile X Syndrome studies →

Open to participants now

11 of the 82 studies in Fragile X Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.

This study: 9 Years to 18 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Fragile X Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to \< 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose, pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg, while Part 2 is double-blind (DB) and randomized between two treatment groups (Study Drug and Placebo).

Read the detailed description

In amendment 4 the enrollment age range what changed to allow enrollment in participants as young as 9 years of age. This only affects Part 2 as Part 1 was completed prior to this amendment.

03

Conditions studied

  • Fragile X Syndrome

Browse trials for

04

Who can participate

Ages eligible
9 Years to 18 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Patient is male adolescent aged 9 to \< 18 years. 2. Patient has FXS with a molecular genetic confirmation of the full fragile X mental retardation-1 (FMR1) mutation (≥ 200 CGG repetitions).

    3. Current treatment with ≤ 3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications. If the subject is on 3 prescribed psychoactive medications and, in addition, is taking either a psychoactive over-the-counter medication (eg, melatonin, Benadryl, etc.) or CBD products, the investigator is encouraged to discuss eligibility with the medical monitor.

    4. Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug. Every effort should be made to keep dosing stable throughout the study.

    5. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks before screening and must remain stable during the period between screening and the commencement of study drug. Every effort should be made to keep dosing stable throughout the study.

    6. Patients with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure-free for 3 months before screening or must be seizure-free for 2 years if not currently receiving anti-epileptics.

    7. Behavioral and other non-pharmacological treatments/interventions must be stable for 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug, and throughout the study. Minor changes in hours or times of therapy that are not considered will not be exclusionary. Changes in therapies provided through a school program, due to school vacations, are allowed.

    8. Patient must be willing to practice barrier methods of while on study, if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.

    9. Patient has a parent(s), legal authorized guardian(s), or consistent caregiver(s).

    10. Patient and caregiver are able to attend the clinic regularly and reliably. 11. Patient's parent(s), legal authorized guardian(s), or consistent caregiver(s) is able to understand and sign an form to participate in the study.

    12. Patient must provide assent for participation in the study if the patient has the cognitive ability to provide assent.

    13. To participate in the Part 1 PK only: subjects must be able to swallow capsules.

Exclusion criteria

Exclusion Criteria:

Diagnosis and main criteria for inclusion:

The eligibility criteria are the same for all parts of the study except for Part 1 (PK), where patients must be able to swallow capsules and must weigh at least 75 lbs (34 kg) to receive the 50 mg dose.

Patient Inclusion Criteria

  1. Patient is male adolescent aged 12 to \< 18 years.
  2. Patient has FXS with a molecular genetic confirmation of the full fragile X mental retardation-1 (FMR1) mutation (≥ 200 CGG repetitions).
  3. Current treatment with ≤ 3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications.
  4. Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug.
  5. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks before screening and must remain stable during the period between screening and the commencement of study drug.
  6. Patients with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure-free for 3 months before screening or must be seizure-free for 2 years if not currently receiving anti-epileptics.
  7. Behavioral and other non-pharmacological treatments/interventions must be stable for 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug, and throughout the study. Minor changes in hours or times of therapy that are not considered will not be exclusionary. Changes in therapies provided through a school program, due to school vacations, are allowed.
  8. Patient must be willing to practice barrier methods of while on study, if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.
  9. Patient has a parent(s), legal authorized guardian(s), or consistent caregiver(s).
  10. Patient and caregiver are able to attend the clinic regularly and reliably.
  11. Patient's parent(s), legal authorized guardian(s), or consistent caregiver(s) is able to understand and sign an form to participate in the study.
  12. Patient must provide assent for participation in the study if the patient has the cognitive ability to provide assent.
  13. To participate in the Part 1 PK only: patients must be able to swallow capsules.

Patient Exclusion Criteria

  1. Inability to successfully complete the NIH-TCB picture vocabulary and oral reading assessments at screening and baseline for Part 2 (DB). Patient must be able to complete these assessments at baseline to be randomized into Part 2; care should be taken that a patient enrolled into Part 1 (PK) possesses this ability if their desire is to continue to Part 2. The ability to complete the NIH-TBC oral reading and picture vocabulary subtest at baseline is defined as the ability to complete both subtests, with (1) confirmation from the clinician administering that the test administrations are valid (noted on the administration form), and (2) generation of valid test scores for each test.
  2. History of, or current cardiovascular, renal, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cerebrovascular, or other systemic disease that would place the patient at risk or potentially interfere with the interpretation of the safety, tolerability, or efficacy of the study drug.

    • Common conditions such as mild hypertension, etc. are allowed per the PI's judgment as long as they are stable and controlled by medical therapy that is constant for at least 4 weeks before randomization.
  3. Renal impairment, defined as serum creatinine > 1.25 × at screening.
  4. Cirrhosis, unstable chronic liver disease or acute liver disease. Hepatic impairment, defined as or aspartate aminotransferase elevation > 2 × ULN at screening. Note: liver function tests may be repeated after 1 week to evaluate return to acceptable limits; if liver function tests remain elevated, patient is ineligible to participate. Subjects with stable chronic on oral anti-viral therapy and subjects cured of chronic may be allowed. Subjects with Gilbert syndrome are allowed.
  5. Clinically significant abnormalities, in the PI's judgment, in safety laboratory tests, vital signs, or 12-lead , as measured during screening.
  6. History of alcohol abuse at any time in life or history of other substance abuse within the past year, according to PI's assessment.
  7. Significant hearing or visual impairment that may affect the patient's ability to complete the test procedures.
  8. Concurrent major psychiatric condition (eg, major depressive disorder, schizophrenia, or bipolar disorder) as confirmed by the PI. Patients with additional diagnosis of autism spectrum disorder or anxiety disorder will be allowed.
  9. Subject has active diseases that would interfere with participation, such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.
  10. Subject is planning to commence psychotherapy or CBT within 4 weeks prior to screening.
  11. Patient is an immediate family member of anyone employed by the sponsor, PI, or study staff.
  12. Patient has weight \< 25 kg or a greater than the 97th percentile for his age according to the Centers for Disease Control and Prevention (refer to Appendix 1). To participate in the Part 1 cohort receiving 50 mg dose, patient must weigh ≥ 75 lbs (34 kg).
  13. Patient has participated in another clinical trial within the 30 days before screening.

    -

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Active comparator
    Study Drug

    Subjects will receive 15 mg BID or 25mg BID dose of BPN14770

    Drug: zatolmilast

  • Placebo comparator
    Placebo Arm

    Subjects will receive matching Placebo

    Drug: Placebo

Interventions

  • Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo

    Also known as: BPN14770

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. NIH Toolbox Cognitive Battery cognition crystallized composite score

    The change from baseline to Week 13 in the NIH Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC), which is calculated from the Picture Vocabulary and Oral Reading domains.

    Time frame: 13 Weeks

Secondary outcomes

  1. NRS patient-specific behaviors within the domains of Daily Function, Language, and Academic Skills.

    Change from baseline to Week 13 in Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skills.

    Time frame: 13 Weeks

  2. CaGI-I for the general domains of Daily Function, Language, and Academic Skills.

    Change from baseline to Week 13 Caregiver Global Impression of Improvement (CaGI-I) for the general domains of Daily Function, Language, and Academic Skills.

    Time frame: 13 Weeks

  3. Investigator rated (CGI-I) for the general domains of Daily Function, Language, and Academic Skills

    Change from baseline to Week 13 Clinical Global Impression Improvement - Investigator rated (CGI-I) for the general domains of Daily Function, Language, and Academic Skills

    Time frame: 13 Weeks

  4. NRS scores based on patient-specific behaviors within the domain of Emotions/Behaviors

    Change from baseline to Week 13 NRS scores based on patient-specific behaviors within the domain of Emotions/Behaviors

    Time frame: 13 Weeks

  5. CaGI-I for the general domain of Emotions/Behaviors

    Change from baseline to Week 13 CaGI-I for the general domain of Emotions/Behaviors

    Time frame: 13 Weeks

  6. The NIH-TCB domains of Picture Vocabulary, Oral Reading Recognition, and Pattern Comparison Processing Speed

    Change from baseline to Week 13 the NIH-TCB domains of Picture Vocabulary, Oral Reading Recognition, and Pattern Comparison Processing Speed

    Time frame: 13 Weeks

  7. Vineland-3 Adaptive Behavior Scale (Vineland-3)

    Change from baseline to Week 13 Vineland-3 Adaptive Behavior Scale (Vineland-3)

    Time frame: 13 Weeks

  8. Verbal Knowledge test from the Stanford Binet (ed 5) (SB-5) IQ assessment

    Change from baseline Verbal Knowledge test from the Stanford Binet (ed 5) (SB-5) IQ assessment

    Time frame: 13 Weeks

07

Study locations

17 sites
  • Amnova Clinical Research
    Irvine, California 92604, United States
  • Thompson Autism & Neurodevelopment Center - CHOC
    Orange, California 92868, United States
  • UC Davis
    Sacramento, California 95817, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • U Mass
    Worcester, Massachusetts 01655, United States
  • Icahn School of Medicine at Mount Sinai Hospital
    New York, New York 10029, United States
  • Cincinatti Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Clinic for Special Children
    Strasburg, Pennsylvania 17579, United States
  • Greenwood Genetic Center
    Greenville, South Carolina 29605, United States
  • University of Utah and Primary Childrens Hospital
    Salt Lake City, Utah 84113, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Sep 2025, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Dec 20, 2021
StartActual
Mar 29, 2022
Primary completionActual
Sep 2, 2025
CompletionActual
Sep 2, 2025
Results delay requested
Aug 27, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05163808
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Mar 29, 2022
Primary completion
Sep 2, 2025
Completion
Sep 2, 2025
Last update
Aug 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BPN14770

Start the discussion